Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in previously treated advanced cholangiocarcinoma (FIGHT-202)
NCT02924376Phase 2Completed
- Sponsor
- Incyte
- Start
- Jan 2017
- Primary completion
- Feb 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 12
01
Overview
Phase 2, open-label trial of pemigatinib in cholangiocarcinoma (CCA) (3 arms), sponsored by Incyte. Primary endpoint: Objective Response Rate in Participants With FGFR2 Rearrangements or Fusions up to 1527 days. Started Jan 2017; status: completed.
02
Drugs
pemigatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02924376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924376.